

**Contact: Large Scale Biology Corporation**  
(707) 446-5501  
Daniel J. Moriarty,  
Vice President, Corporate Affairs  
(707) 469-2347 [dan.moriarty@lsbc.com](mailto:dan.moriarty@lsbc.com)  
or  
Burns McClellan (212) 213-0006  
Kathy L. Jones, Ph.D. (Media)  
[kjones@ny.burnsmc.com](mailto:kjones@ny.burnsmc.com)

*For immediate release:*

## **PLURIGEN™ CM: Large Scale Biology Corporation's Stem Cell Growth Factor Product Now Available to Research Community**

Vacaville, California, March 25, 2002 – Large Scale Biology Corporation (Nasdaq: LSBC) today announced the availability of its new PLURIGEN™ CM stem and progenitor cell growth factor formulation. The product, first previewed last December at the annual meeting of the American Society of Hematology (ASH), may now be obtained by the research community through the Company's website, [www.lsbc.com/therapeutics](http://www.lsbc.com/therapeutics). Company scientists report strong interest from both academic, commercial and government research institutions.

"The successful development of PLURIGEN™ CM demonstrates LSBC's successful application of our integrated core technologies to the development of innovative products," said John D. Fowler, President of LSBC. The Company will make PLURIGEN™ CM available initially to select institutions for the purpose of expanding the applications and utilities of the new product. "Introducing a novel product, ready to ship ahead of schedule, is a way of strengthening our partner relationships. It reinforces LSBC's commitment to the accelerated commercialization of our many technologies both directly and through commercial alliances," said Dr. N. Leigh Anderson, Chief Scientific Officer of LSBC.

### *New product with novel features*

LSBC's PLURIGEN™ CM is a stabilized formulation of hematopoietic growth factors exhibiting strong proliferative activity on a wide variety of stem and progenitor cells. A body of work conducted by LSBC, its CRADA partner the Naval Medical Research Center, and its collaborator SRI International, has demonstrated that PLURIGEN™ CM reliably induces the proliferation of human bone marrow, cord blood and peripheral blood derived CD34<sup>+</sup> hematopoietic progenitor cells. Cells so expanded retain their plasticity, their ability to engraft SCID/NOD mice, and their capability to be further differentiated into major blood cell lineages upon exposure to additional cytokines. LSBC's work with other types of cells, including proliferation of human endothelial cells and production of dendritic cell precursors, suggests that PLURIGEN™ CM is a widely applicable growth factor formulation. As a single agent,

PLURIGEN™ CM can match or surpass optimal combinations of other growth factors. Further differentiating PLURIGEN™ CM is the product's wide species range, acting on human, non-human primate, porcine and rodent cells *in vitro*. Experimental work *in vivo* with a murine tumor challenge model suggests that PLURIGEN™ CM may also be used as a vaccine adjuvant through its ability to expand dendritic cells (DC). The relevant studies were presented at the ASH meeting last December.

The strong presence of LSBC at the ASH Annual Meeting and the successful introduction of its first product to meet the demands of researchers in the stem cell and hematology communities underscore LSBC's commitment to the aggressive development of products for hematology, oncology and immunotherapy. Long-term investment strategy in these areas has focused on product categories for which LSBC anticipates considerable medical demand and long-term growth. The PLURIGEN™ CM cell culture product intended for research applications is the first in a portfolio of related inventions, which LSBC intends to produce and market with partners or independently.

#### About Large Scale Biology Corporation

Large Scale Biology uses its proteomics, functional genomics and biomanufacturing technologies to develop and manufacture personalized drugs, vaccines and diagnostics for rapid identification and effective treatment of disease. Corporate offices and the Genomics Division are headquartered in Vacaville, California; the Company's Proteomics Division is located in Germantown, Maryland; and the Company's Bioprocessing Division is located in Owensboro, Kentucky. For more information about Large Scale Biology Corporation, visit the Company's website at [www.lsbc.com](http://www.lsbc.com).

*This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on our current plans, expectations, estimates, and projections and management's beliefs about our future performance. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates" or variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict and which may cause our actual results and performance to differ materially from those expressed or forecasted in any such forward-looking statements. For a further list and description of such risks and uncertainties see the reports filed by Large Scale Biology Corporation with the Securities Exchange Commission. Unless required by law, Large Scale Biology Corporation undertakes no obligation to update publicly any forward-looking statements.*

*GENEWARE® is a registered trademark of Large Scale Biology Corporation. LSBC™ and PLURIGEN™ CM are trademarks of Large Scale Biology Corporation.*